AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03354715 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Rapid prototyping Denture base
Description: The introduction of rapid prototyping (RP)Stereo lithography (SLA) technology, which mainly depends on addition of layers of materials which would be polymerized using a light curing unit. It consists of a bath of photo polymerized liquid and ultraviolet unit for curing these layers, that would bond to each other till forming the full object. SLA has many advantage as high accuracy, high mechanical strength, smooth surface finish with close tolerance and fine details printing, but it has some limitation as it is only limited Material, in addition to the high material and equipment cost.
Study NCT03354715 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Heat Cured Conventional Complete Denture
Description: it is the main treatment for most of completely edentoulous Cases
Study NCT03624920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THN102 Dosage A
Description: THN102 Dosages A: placebo
Study NCT03624920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THN102 Dosage B
Description: THN102 Dosage B : 200mg/2mg
Study NCT03624920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THN102 Dosage C
Description: THN102 Dosage C: 200mg/18mg
Study NCT02344082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Description: The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
Study NCT04563715 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV counseling and testing
Description: Receive HIV testing risk assessment and advice about risk reduction and future testing.
Study NCT04563715 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV counseling and testing
Description: Receive HIV testing risk assessment and advice about risk reduction and future testing.
Study NCT04563715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Network intervention
Description: Key individuals are trained to provide advice about regular testing and risk reduction.
Study NCT01733810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cessation of Acid Suppressing Medications
Description: Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.
Study NCT01838473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Administration of nicotine
Description: Oral pouch 1g, single dose. One pouch administered over 30 minutes.
Study NCT01838473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Administration of nicotine
Description: Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
Study NCT02706483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide
Study NCT05995691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 501
Description: SC injection
Study NCT05995691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: SC injection
Study NCT01838473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Administration of nicotine
Description: Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
Study NCT01382537 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InterX 5000
Description: A computer driven electrical stimulation unit that contains a cutaneous impedance sensor.
Study NCT04834804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: 12 weeks of exercise training
Study NCT02799849 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sleep and metabolism assessment
Study NCT01382537 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: InterX 5000
Description: Placebo treatment
Study NCT00430066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: 400 mg/die for 6 months
Study NCT01567150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel Dressing
Description: Topical wound dressing
Study NCT01997866 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: STOP-BANG Scoring Model
Description: Patients with Congestive Heart Failure on non-Intensive Care Unit Medical Services and/or visiting our outpatient Congestive Heart Failure Clinic will be administered the STOP-BANG Scoring Model to determine whether they are considered high-risk or low-risk for Sleep Apnea.
Study NCT04391504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAC combined with radiofrequency ablation group
Description: Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
Study NCT01997866 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnogram Sleep Study
Description: Patients determined by the STOP-BANG Scoring Model to be high-risk for Sleep Apnea will be referred to the Sleep Center physicians for evaluation and treatment. If medically indicated, a Polysomnogram Sleep Study will be performed.
Study NCT01680432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic fresh cheese
Description: Participants in the intervention group were instructed to drink 30 grams of fresh cheese enriched with probiotics daily for 30 consecutive days.
Study NCT01680432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Regular Cheese
Study NCT03271359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: Initial EMDR session of up to three hours; about one week later, follow-up session of up to one hour
Study NCT01845480 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness coaching
Description: Wellness coaching that includes modeling, goal setting, self-monitoring, social support, and health behavior education
Study NCT01845480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness coaching
Description: Wellness coaching that includes modeling, goal setting, self-monitoring, social support, and health behavior education
Study NCT00973063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine sterile gloving
Description: routinely new sterile gloving just before sampling
Study NCT02910011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanodox 1% (doxycycline monohydrate hydrogel)
Description: Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner
Study NCT03168334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-123 Lotion
Description: Tazarotene 0.045% Lotion
Study NCT03168334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-123 Vehicle Lotion
Description: Vehicle Lotion
Study NCT00859742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA, integrated PET/CT
Description: EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.
Study NCT03511456 — intervention group
Intervention type: PROCEDURE
Intervention: PELD operation
Description: Under local anesthesia, the introduction of 20G needles could be performed with fluoroscopy. After the needle traveled through TFS space, extremely care was needed to avoid nerve root injury.~Discography was recommended. The following steps were performed as usual: the needle was replaced by a guide wire; a 9 mm incision was made in the skin; a tapered cannulated dilator was inserted along the guide wire; and finally a working cannula was inserted.~The remove of disc was performed carefully under endoscope. The first step was to locate the annulus fibrosis of L5/S1 disc, then by using nerve dissector and bipolar elliquence, soft tissue including fat tissue, muscle and fibers of ligaments were pushed cephalad until the blue stained herniated disc was visible and removed.
Study NCT03596450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will be prescribed commercially available semaglutide s.c. and will be instructed to initiate treatment with semaglutide s.c. according to the approved label. The study doctor will determine the intended maintenance dose of semaglutide, as well as changes to the maintenance dose thereafter.
Study NCT03596450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.
Study NCT03271359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PC
Description: Initial PC session of up to three hours; about one week later, follow-up session of up to one hour
Study NCT02136056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management program (SMP)
Description: A self-management course
Study NCT02160444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT plus Parent as CBT Coach Training
Description: Standard CBT for treatment of anxiety disorders in youth is completed by the children while their primary caregiver receives training in the same cognitive behavioral skills, how to recognize when he or she is accommodating his or her child's anxiety, and how to create and implement exposure activities.
Study NCT00772109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.1 mL, Intradermal
Study NCT00985088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340274A
Description: one or two intramuscular injections
Study NCT00772109 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.5 mL, Intramuscular
Study NCT01379300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration
Study NCT01379300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration
Study NCT00651365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38877605
Study NCT01403116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate
Description: Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
Study NCT01403116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical testosterone gel
Description: Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
Study NCT00985088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340273A
Description: one or two intramuscular injections
Study NCT00985088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: One injection
Study NCT03125148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enteral stenting
Description: Enteral stent for malignant duodenal obstruction
Study NCT03125148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enteral stenting
Description: Enteral stent for malignant duodenal obstruction
Study NCT02016365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA
Study NCT02016365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: 750 mg/day (500 mg +250mg orally) continuously
Study NCT03730038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of pitavastatin 4 mg qd for 12 weeks
Description: Treatment of pitavastatin 4 mg qd for 12 weeks
Study NCT03730038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life-style modification
Description: Nutritional support with the meal less than 65% of carbohydrate, less than 30% of fat. Exercise 3-4 times, 30 min
Study NCT01491815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-biological DMARD's
Description: Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, Iceland, and the Netherlands)
Study NCT03134339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine saline 0.00mcg/kg/s
Description: saline 0.00mcg/kg/s
Study NCT03134339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0.24 mcg/kg/s
Description: nicotine 0.24 mcg/kg/s
Study NCT03134339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0.048 mcg/kg/s
Description: nicotine 0.048 mcg/kg/s
Study NCT03134339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0.024 mcg/kg/s
Description: nicotine 0.024 mcg/kg/s
Study NCT03853564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-Feedback Intervention
Description: Mothers and infants of the VFG arm will participate to a 6-session video-feedback intervention structured as follows: 4 sessions of video-review discussions with a trained clinician + 2 sessions of integrative intervention aimed at translating into practical caregiving the insights developed during the video-review discussions.
Study NCT02683421 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tilmanocept
Study NCT02683421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilmanocept
Study NCT01358747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEACOPPesc
Study NCT01358747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPPesc - ABVD - PET2
Study NCT03167268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene
Study NCT03167268 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01778634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin intravenous 20 mg/kg every 24 h x 3 days
Study NCT01778634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D5W
Study NCT01491815 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cimzia
Description: Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
Study NCT04196881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knowledge Improvement Program about ADHD
Description: This training program will cover an overview of ADHD, prevalence, causes, symptoms, risk factors, associated impairment, prognosis, and treatment options including behavioral interventions and medication.
Study NCT04277962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triton L and D system for estimation of blood loss at time of vaginal delivery
Description: The Triton L\&D system (Gauss Surgical, Inc., Menlo Park, CA) is an FDA-cleared mobile application on a tablet computer (iPad) that facilitates quantification of blood loss (QBL) by providing an easy to use process and user interface. Dry weights of all potential blood containing substrates are built-in to the device allowing batch weighing with automatic subtraction of dry weights. There is also a V-drape simulator accounting for collected fluids with automatic subtraction of a measured amount of amniotic fluid.
Study NCT03156504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Subjects will receive three IV ketamine infusions at 0.5 mg/kg, infused over 100 minutes.
Study NCT01783912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive / Motivational Individual Sessions
Description: Cognitive Motivational subjects will receive four evidence-based preparatory interventions (motivational interviewing, smoking reduction, practice quit attempt, and pre-quit use of nicotine replacement medication) (25 - 30 minutes each).
Study NCT01783912 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Individual Sessions
Description: Attention control subjects will receive four placebo individual sessions (25-30 minutes each). The session content will reemphasize group discussion of the personal health risks from smoking.
Study NCT01783912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Cognitive Motivational subjects will be asked to take one 21 mg patch/day for 4 weeks.
Study NCT01783912 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Curriculum
Description: Everyone to be put into the experimental or active comparator group will attend 2 group meetings over two weeks each of which lasts 40 minutes. Experience with the Kicking Butts program indicates that this duration is well tolerated by this population. The content of these two group meetings is based on the Kicking Butts program. The Kicking Butts program was initially developed as a cessation intervention, but consistent with the literature about the need to prepare this population to make a quit attempt, has evolved to emphasize preparation for quitting. Topics addressed include the health consequences of smoking, reasons to quit and methods of quitting.
Study NCT01783912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Curriculum
Description: Everyone to be put into the experimental or active comparator group will attend 2 group meetings over two weeks each of which lasts 40 minutes. Experience with the Kicking Butts program indicates that this duration is well tolerated by this population. The content of these two group meetings is based on the Kicking Butts program. The Kicking Butts program was initially developed as a cessation intervention, but consistent with the literature about the need to prepare this population to make a quit attempt, has evolved to emphasize preparation for quitting. Topics addressed include the health consequences of smoking, reasons to quit and methods of quitting.
Study NCT03600987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simultaneous music and reading lyrics
Description: listening to music with singing of the lyrics simultaneously with reading the written lyrics.
Study NCT03600987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming with music
Description: priming by listening to music and singing of the lyrics followed by reading the written lyrics.
Study NCT03600987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: control condition using reading materials without music.
Study NCT04315506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: #EnufSnuff.TXT Intervention
Description: The SGR program will reduce smokeless tobacco until you reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
Study NCT04315506 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enough Snuff Intervention
Description: Participants will be sent the Enough Snuff cessation manual. One weeks after it is sent, participants will then receive text messages from the study team twice a week for ten weeks.
Study NCT04902014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: The individuals will be scheduled for and participate in six biweekly in person SDT based MI sessions. These sessions will take place in the HPCRL at CSU. The MI sessions will be conducted by a PhD student who has been trained by a MI practitioner. Participants will be provided a log book and will be asked to log their PA, with the goal of completing at least 150 minutes of PA per week. They will set biweekly PA goals, which will be discussed in the MI sessions. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
Study NCT04902014 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: These participants will receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting. These participants will not do any other study related activities. At the conclusion of the study, these participants will be offered the chance to participate in one MI session.
Study NCT01491815 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Orencia
Description: Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
Study NCT01491815 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RoActemra
Description: Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week.~Methotrexate: 25mg/week
Study NCT00913055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide acetate
Description: subcutaneous implant